There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="d19680422e86">Hypertrophic cardiomyopathy (HCM) is a heterogeneous
genetic disorder most often caused
by sarcomeric mutations resulting in left ventricular hypertrophy, fibrosis, hypercontractility,
and reduced compliance. It is the most common inherited monogenic cardiac condition,
affecting 0.2% of the population. Whereas currently available therapies for HCM have
been effective in reducing morbidity, there remain important unmet needs in the treatment
of both the obstructive and non-obstructive phenotypes. Novel pharmacotherapies directly
target the molecular underpinnings of HCM, while innovative procedural techniques
may soon offer minimally-invasive alternatives to current septal reduction therapy.
With the advent of embryonic gene editing, there now exists the potential to correct
underlying genetic mutations that may result in disease. This article details the
recent developments in the treatment of HCM including pharmacotherapy, septal reduction
procedures, mitral valve manipulation, and gene-based therapies.
</p>